ABP-2111Na / AB Pharma - LARVOL DELTA

A Phase IIa Randomized and Double-Blind Study for the Safety, Tolerability, PK/PD and Efficacy of a FIC GPR40/GPR120 Dual Agonist ABP2111Na in Participants with Obesity (ECO 2025) - "Introduction: ABP2111Na ("

Clinical • P2a data • PK/PD data • Genetic Disorders • Obesity

A Randomized, Double-Blind, Placebo-Controlled Phase IIb Clinical Study Evaluating the Efficacy and Safety of ABP2111Na Tablets in Overweight/Obese Participants (ChiCTR) - P2 | N=180 | Recruiting | Sponsor: Peking University People's Hospital; Shanghai AB PharmaTech Ltd.

New P2 trial • Obesity

Starting a new phase, 6 drug clinical trial projects of Puyang Oilfield General Hospital successfully passed the project approval [Google translation] (Sohu.com) - "Respiratory Medicine: A multicenter, randomized, double-blind, multiple-dose, dose-escalating, placebo- and positive-controlled Phase IIa clinical study to evaluate the safety, tolerability, and efficacy of TRN-157 nebulizer inhalation in patients with chronic obstructive pulmonary disease (COPD)....Department of Rheumatology and Immunology: A multicenter, randomized, double-blind, placebo-controlled Phase III clinical study to evaluate the efficacy and safety of SHR-1314 injection in adult patients with active psoriatic arthritis....Department of Endocrinology: A randomized, double-blind, placebo-controlled Phase IIb clinical study on the efficacy and safety of ABP2111Na tablets in overweight/obese participants."

New P2a trial • Trial status • Chronic Obstructive Pulmonary Disease • Obesity • Psoriatic Arthritis

Phase Ib clinical trial evaluating the safety, tolerability, pharmacokinetic and pharmacodynamic profile of ABP2111Na tablets in randomized, double-blind, placebo-controlled single and multiple administration dose escalation in patients with type 2 diabetes mellitus (ChiCTR) - P1 | N=30 | Not yet recruiting | Sponsor: The First Affiliated Hospital of Bengbu Medical University; Shanghai AB PharmaTech Ltd.

New P1 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Randomised, Double-Blind, Placebo-Controlled, Multiple Administration Dose Escalation Phase IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profile of ABP2111Na Tablets in Overweight/Obese Subjects (ChiCTR) - P2 | N=30 | Recruiting | Sponsor: Peking University People's Hospital; Shanghai AB PharmaTech Ltd.

New P2 trial • Obesity